Somatic mutations identified in resistant MCL cell lines, including nonsense mutations in tumor necrosis factor receptor-associated factor 2 (TRAF2) and deletions in TRAF3, indicate a shift to the alternative NF-κB pathway (Figure 1) [90]. This evidence concerns the gene NFKB1 and mantle cell lymphoma.